Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15498138 | 0.93 | PRMT5 (0.48) | GPR119KDM1ASTSPRMT5WDR77 | |
| SCHEMBL27379752 | 0.88 | GPR119 (0.50) | GPR119KDM1ASTSPRMT5WDR77 | |
| SCHEMBL18280020 | 0.86 | GPR119 (0.59) | GPR119STSPRMT5WDR77 | |
| SCHEMBL14851987 | 0.86 | CARM1 (0.55) | GPR119STSPRMT5WDR77KDM4E | |
| SCHEMBL29735456 | 0.86 | GPR119 (0.59) | GPR119STSPRMT5WDR77 | |
| SCHEMBL17554496 | 0.86 | GPR119 (0.55) | GPR119KDM1ASTSPRMT5 | |
| SCHEMBL3249107 | 0.86 | STS (0.58) | GPR119STSPRMT5WDR77KDM4E | |
| SCHEMBL17560083 | 0.85 | KDM1A (0.49) | GPR119KDM1APRMT5 | |
| SCHEMBL30388656 | 0.85 | KDM1A (0.49) | GPR119KDM1APRMT5 | |
| SCHEMBL14852116 | 0.84 | GPR119 (0.51) | GPR119STSNR1H2KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2993236-A1 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS | Glaxosmithkline LLC (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2993236-A1 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS | Glaxosmithkline LLC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20130102009-A1 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS | GLAXOSMITHKLINE LLC | 2013-04-25 | — | — | US | disclosed |
| US-20130102009-A1 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS | GLAXOSMITHKLINE LLC | 2013-04-25 | — | — | US | disclosed |
| EP-2558589-A2 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS | Sirtris Pharmaceuticals, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011130595-A2 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130595-A2 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102009-A1 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS | SIRT1, SIRT7, SIRT2 | GPR119 134/4885KDM1A 63/4885STS 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.